Chemotherapy With or Without Bevacizumab as Treatment for Recurrent or Advanced Head and Neck Cancer
This purpose of this study is to determine if adding bevacizumab to chemotherapy improves how well it works when treating patients with recurrent or metastatic head and neck cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from reproducing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Bevacizumab may make tumor cells more sensitive to chemotherapy and stop the growth of head and neck cancer by blocking blood flow to the tumor. The primary objective is to see if the addition of bevacizumab to standard cisplatin-based chemotherapy improves the overall survival of patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The study will enroll 400 participants from many cancer centers in the US. In addition to other conditions for enrollment, at least 6 months must have passed since patients completed prior radiotherapy or chemotherapy. Patients with a history of bleeding related to their cancer or spitting up blood, uncontrolled high blood pressure, heart problems, digestion or swallowing problems, infections, or prior treatment with bevacizumab may not be eligible. Patients with a diagnosis of squamous cell cancer of the skin are not included in this study.